Heatstroke drug dosage optimization system integrating multi-source clinical data
By collecting, fusing, and optimizing multi-source clinical data, and using the physiological event anchor point of heatstroke to calibrate the timing, the problem of insufficient drug dosage adjustment capability in existing technologies is solved, and safe and reliable efficacy assessment and adaptive adjustment under fault conditions are realized.
Patent Information
- Application Number
- CN202611242446.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-17
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies only use core body temperature as the core for dose determination, which is incomplete in terms of indicator coverage and makes it difficult to fully characterize drug efficacy. Furthermore, the lack of a multi-channel data time-series calibration mechanism results in insufficient adaptive adjustment capability of heatstroke drug dose.
The data acquisition module collects multi-source clinical data in parallel, performs global time-series calibration based on physiological events of heatstroke, the data fusion module performs dynamic anchoring correction of the fusion time-series benchmark, and the dosage optimization module performs isolated extrapolation of drug efficacy increments. This ensures the consistency of the time-series benchmark of multi-source data and the reliability of acquisition quality, and avoids drug efficacy calculation deviations caused by communication interruptions.
It improves the adaptive adjustment capability of heatstroke drug dosage, ensures the safety and reliability of drug efficacy evaluation under fault conditions, and reduces timing errors and deviations in drug dosage optimization results.
Smart Images

Figure CN123120187A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of clinical data processing technology, and in particular to a heatstroke drug dosage optimization system that integrates multi-source clinical data. Background Technology
[0002] As global warming continues to intensify, extreme heatwaves are occurring more frequently worldwide, making the threat of heat stress to human health and safety a major concern. In high-temperature environments, heatstroke is the most serious acute illness caused by heat stress, characterized by its rapid onset, rapid progression, and extremely high mortality rate. Based on the cause and susceptible populations, heatstroke can be divided into two categories: typical heatstroke and exertional heatstroke. Exertional heatstroke primarily occurs in healthy young adults who need to work in high-heat environments or engage in strenuous exercise. Therefore, developing and implementing targeted protective measures for this population is of paramount practical importance.
[0003] Chinese Patent Publication No. CN120412885A discloses a method for optimizing drug dosage based on clinical data of heatstroke, comprising: S1, completing drug preparation; S2, selecting several comparison samples, inducing physical heatstroke in the comparison samples to obtain several induced samples, and administering the drug to several induced samples to obtain several test samples; S3, obtaining the core temperature, blood and tissue of each sample; S4, filtering out abnormal data of the samples based on the core temperature, and obtaining the lipopolysaccharide concentration and tight junction protein concentration of each retained sample; S5, based on the core temperature of each test sample, the core temperature of each induced sample, and the lipopolysaccharide concentration of each test sample, determines whether the drug dosage is qualified. Based on the core temperature of each comparison sample and the average concentration of tight junction proteins in each test sample, it determines whether the drug dosage needs to be adjusted. When adjusting the drug dosage, steps S1-S5 are repeated. If it is still determined that the drug dosage should be adjusted to the corresponding value, the drug dosage is adjusted based on the temperature change parameter until the drug dosage is deemed qualified. Therefore, the drug dosage optimization method based on heatstroke clinical data only uses core body temperature as the core for dosage determination, resulting in incomplete indicator coverage, difficulty in fully characterizing drug efficacy, and the lack of a multi-channel data time-series calibration mechanism, leading to insufficient adaptive adjustment capability of heatstroke drug dosage. Summary of the Invention
[0004] To address this, the present invention provides a heatstroke drug dosage optimization system that integrates multi-source clinical data, in order to overcome the problems of existing technologies that rely solely on core body temperature as the core for dosage determination, resulting in incomplete indicator coverage, difficulty in fully characterizing drug efficacy, and insufficient adaptive adjustment capability of heatstroke drug dosage due to the lack of a multi-channel data time-series calibration mechanism.
[0005] To achieve the above objectives, the present invention provides a heatstroke drug dosage optimization system that integrates multi-source clinical data, comprising: The data acquisition module is used to collect multi-source clinical data from users in parallel through several detection devices, and to determine whether the sampling capacity of multi-source clinical data meets the requirements based on the sampling interval of the multi-source clinical data. The data fusion module is used to fuse the multi-source clinical data to obtain a multi-source fusion feature vector, and to perform dynamic anchoring and correction of the fusion timeline benchmark based on the arrival time of the previous valid data from a single data source. The dosage optimization module is used to output a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and send the dosing adjustment command to the dosing actuator to perform an isolation simulation of the pharmacodynamic increment during the interruption based on the dosing completion time of the previous dosing by the dosing actuator.
[0006] Furthermore, the data acquisition module is used to determine that the acquisition capability of the multi-source clinical data meets the requirements when the sampling interval of the multi-source clinical data is within the allowable range; The data acquisition module is used to transmit the multi-source clinical data to the fusion terminal.
[0007] Furthermore, the data acquisition module is used to determine that the acquisition capability of the multi-source clinical data does not meet the requirements when the sampling interval of the multi-source clinical data exceeds the allowable range; The data acquisition module is used for global time-series calibration based on physiological event anchors of heatstroke.
[0008] Furthermore, the data acquisition module is used to extract multi-channel physiological features through a sliding window to form a candidate set of physiological event anchors for heatstroke, and to remove false anchors based on the physiological priors of heatstroke. The data acquisition module is used to match cross-channel source anchor points, fit the clock drift model of each channel, correct the timestamps of all sampling points, verify the anchor point deviation and iteratively optimize, and complete the timing alignment of multi-source non-uniform sampling data.
[0009] Furthermore, the data fusion module is used to determine that the multi-source fusion feature vector is complete based on the fact that the arrival time of the previous valid data from the single data source is not earlier than the start time of the current fusion cycle. The data fusion module is used to fuse the multi-source clinical data to obtain a multi-source fusion feature vector.
[0010] Furthermore, the data fusion module is used to determine that the multi-source fusion feature vector is incomplete if the arrival time of the previous valid data from the single data source is earlier than the start time of the current fusion cycle. The data fusion module is used to perform dynamic anchoring correction of the fusion time series benchmark.
[0011] Furthermore, the data fusion module is used to dynamically select at least two highly reliable data sources as time-series reference channels and extract physiological events to generate flexible time-series beats; The data fusion module is used to map historical data from disconnected data sources to a flexible time-series axis and redefine the effective boundary, quantify the time-series lag offset to obtain the risk coefficient, and adopt a differentiated fusion strategy based on the risk coefficient. The data fusion module is used to continuously monitor the communication status of the reference channel and re-elect the reference channel when an anomaly occurs.
[0012] Furthermore, the dosage optimization module determines that the command execution capability of the drug delivery actuator meets the requirements if the completion time of the previous drug delivery is not earlier than the start time of the current processing cycle. The dosage optimization module is used to output a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and send the dosing adjustment command to the dosing actuator.
[0013] Furthermore, the dosage optimization module is used to determine that the command execution capability of the drug delivery actuator does not meet the requirements if the time of completion of the previous drug delivery by the drug delivery actuator is earlier than the start time of the current processing cycle. The dosage optimization module is used to perform isolation simulation of drug efficacy increment during interruption.
[0014] Furthermore, the dosage optimization module is used to switch to the drug efficacy increment isolation simulation mode based on the identified fault characteristics; The dosage optimization module is used to define an isolation window based on the start of the current treatment cycle in order to perform a one-way deduction of drug elimination to obtain a conservative efficacy state. The dosage optimization module is used to output a conservative dosing adjustment strategy based on the conservative pharmacodynamic state.
[0015] Compared with existing technologies, the beneficial effects of the present invention are as follows: The system of the present invention, by setting up a data acquisition module, collects multi-source clinical data of users in parallel through several detection devices. It determines whether the sampling capacity of multi-source clinical data meets the requirements based on the sampling interval of multi-source clinical data, and ensures the uniformity of multi-source data time series benchmark and reliable acquisition quality based on global time series calibration of heatstroke physiological event anchor points. By setting up a data fusion module, the multi-source clinical data is fused to obtain a multi-source fusion feature vector. The fusion time series benchmark is dynamically anchored and corrected according to the arrival time of the previous valid data from a single data source, solving the problem of feature fusion distortion caused by single-source data disconnection and data expiration, and improving the fault tolerance and integrity of multi-source data fusion. By setting up a dosage optimization module, the system outputs a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and sends the dosing adjustment command to the dosing actuator. Based on the previous dosing completion time of the dosing actuator, the system performs isolated extrapolation of drug efficacy increment during the interruption period, avoiding concentration calculation deviation caused by the superposition of unknown drug efficacy increment under communication interruption, ensuring the safety and reliability of drug efficacy assessment under fault conditions, and improving the adaptive adjustment capability of heatstroke drug dosage.
[0016] Furthermore, the system of the present invention performs global time-series calibration based on the sampling interval of multi-source clinical data and anchor points of heatstroke physiological events. Due to fluctuations in the power supply of the sensor front-end circuit, the timing accuracy of the sampling clock of the analog-to-digital conversion module drifts, causing the time interval between two adjacent samples to exceed the allowable range. This results in excessive deviation of the sampling interval of multi-source clinical data. By performing global time-series calibration based on anchor points of heatstroke physiological events, physiological characteristic events of heatstroke such as pulse peak and arterial blood pressure systolic peak can be used as natural time-series anchor benchmarks. Homologous physiological anchor points are selected to fit the clock drift model of each channel, achieving global calibration of the timestamps of all sampled data. This reduces the deviation of drug dosage optimization results caused by time-series errors and further improves the adaptive adjustment capability of heatstroke drug dosage.
[0017] Furthermore, the system of the present invention dynamically anchors and corrects the fusion timeline benchmark based on the arrival time of the previous valid data from a single data source. If the communication channel of a certain data source is interrupted, the fusion unit may fail to receive new valid data from that data source at the start of the current fusion cycle. This results in at least one data source having its previous valid data arrival time remaining at the point in the previous fusion cycle, causing its previous valid data arrival time to be earlier than the start time of the current fusion cycle. Through dynamic anchoring and correction of the fusion timeline benchmark, a high-priority clinical data source with stable communication can be dynamically selected as the timeline anchor benchmark. A flexible timeline axis is constructed based on physiological events in the benchmark channel, recalibrating the valid time boundary of expired historical data from the interrupted data source, quantifying the risk of timeline lag, suppressing drug dosage assessment bias caused by timeline misalignment, and further improving the adaptive adjustment capability of heatstroke drug dosage.
[0018] Furthermore, the system of the present invention, based on the previous dosing completion time of the dosing actuator and the pharmacodynamic increment isolation simulation during the interruption, addresses the issue that, due to the interruption of the communication link between the dosing actuator and the dosage optimization module, the dosing actuator failed to successfully complete the infusion operation corresponding to the received dosing adjustment command. Consequently, the previous dosing completion time recorded in the dosing completion time register remains at the time when the dosing interruption occurred, instead of progressing to the normal completion time of the current processing cycle. This results in the previous dosing completion time of the dosing actuator being earlier than the start time of the current processing cycle. By performing pharmacodynamic increment isolation simulation during the interruption, the pharmacodynamic increment isolation simulation can be initiated when communication is interrupted and the dosing execution status cannot be confirmed. This isolates the pharmacodynamic increment corresponding to the uncertain dosing command, performs conservative pharmacodynamic calculations based solely on the drug natural elimination model, blocks the risk of concentration overestimation caused by the continuous accumulation of unknown pharmacodynamic increments, ensures uninterrupted system monitoring during the fault period, avoids generating dangerous dosing plans based on erroneous pharmacodynamic states, and further improves the adaptive adjustment capability of heatstroke drug dosage. Attached Figure Description
[0019] Figure 1 This is a block diagram of the overall structure of the heatstroke drug dosage optimization system that integrates multi-source clinical data, as described in an embodiment of the present invention. Figure 2 This is a flowchart illustrating the global temporal calibration process based on physiological event anchors of heatstroke in the heatstroke drug dosage-assisted optimization system that integrates multi-source clinical data, as described in this embodiment of the invention. Figure 3 This is a flowchart illustrating the dynamic anchoring and correction process of the fusion time-series benchmark in the heatstroke drug dosage auxiliary optimization system that integrates multi-source clinical data, as described in an embodiment of the present invention. Figure 4This is a flowchart illustrating the logic of the interruption-period drug efficacy increment isolation extrapolation and correction process of the heatstroke drug dosage auxiliary optimization system that integrates multi-source clinical data, as described in an embodiment of the present invention. Detailed Implementation
[0020] To make the objectives and advantages of the present invention clearer, the present invention will be further described below with reference to embodiments; it should be understood that the specific embodiments described herein are merely for explaining the present invention and are not intended to limit the present invention.
[0021] Preferred embodiments of the present invention will now be described with reference to the accompanying drawings. Those skilled in the art should understand that these embodiments are merely illustrative of the technical principles of the present invention and are not intended to limit the scope of protection of the present invention.
[0022] It should be noted that in the description of this invention, the terms "upper", "lower", "left", "right", "inner", "outer", etc., which indicate directions or positional relationships, are based on the directions or positional relationships shown in the accompanying drawings. This is only for the convenience of description and is not intended to indicate or imply that the device or element must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, it should not be construed as a limitation of this invention.
[0023] Furthermore, it should be noted that, in the description of this invention, unless otherwise explicitly specified and limited, the terms "installation," "connection," and "linking" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection of two components. Those skilled in the art can understand the specific meaning of the above terms in this invention according to the specific circumstances.
[0024] Please see Figure 1 The diagram shown is an overall structural block diagram of the heatstroke drug dosage optimization system that integrates multi-source clinical data according to an embodiment of the present invention. The system described in this embodiment includes: The data acquisition module is used to collect multi-source clinical data from users in parallel through several detection devices, and to determine whether the sampling capacity of multi-source clinical data meets the requirements based on the sampling interval of the multi-source clinical data. The data fusion module, which is connected to the data acquisition module, is used to fuse the multi-source clinical data to obtain a multi-source fusion feature vector, and to perform dynamic anchoring and correction of the fusion timeline benchmark based on the arrival time of the previous valid data from a single data source. The dosage optimization module, which is connected to the data fusion module, is used to output a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and send the dosing adjustment command to the dosing actuator to perform an isolation simulation of the pharmacodynamic increment during the interruption based on the dosing completion time of the previous dosing by the dosing actuator.
[0025] Specifically, several testing devices include electrocardiogram monitors, invasive arterial blood pressure sensors, and pulse wave sensors.
[0026] Specifically, multi-source clinical data includes body temperature data, arterial blood pressure data, pulse wave data, and blood oxygen saturation data.
[0027] Specifically, the multi-source fusion feature vector is a standardized multi-dimensional feature set after time-series calibration, anomaly correction, normalization, and fusion processing of multi-source clinical data.
[0028] Specifically, a valid data point from a single data source is the monitoring sample from the previous valid monitoring channel that has been timestamped and is free from distortion.
[0029] Specifically, the pharmacokinetic model for heatstroke is an individualized compartmental dynamics model corrected for the pathological characteristics of heatstroke. The model receives real-time physiological, organ function, and circulatory status parameters of the patient represented by multi-source fusion feature vectors, dynamically corrects kinetic parameters such as drug distribution volume and clearance rate, and deduces the temporal evolution trend of drug concentration in the body under different infusion regimens. It combines preset therapeutic targets to solve for optimal infusion parameters, superimposes medical safety constraints, and finally outputs dosing adjustment instructions.
[0030] Specifically, the dosing adjustment instructions include dosing frequency, single dose, and duration of dosing.
[0031] Specifically, drug delivery actuators include nasogastric infusion pumps, microinfusion pumps, and intravenous infusion pumps.
[0032] In this embodiment, the system employs a data acquisition module to collect multi-source clinical data from users in parallel using multiple detection devices. It determines whether the sampling capacity of the multi-source clinical data meets requirements based on the sampling interval duration and performs global temporal calibration based on the physiological event anchor point of heatstroke to ensure a unified temporal benchmark and reliable acquisition quality. A data fusion module fuses the multi-source clinical data to obtain a multi-source fusion feature vector. Dynamic anchoring and correction of the fusion temporal benchmark are performed based on the arrival time of the previous valid data from a single data source, resolving feature fusion distortion caused by single-source data disconnection and data expiration, thus improving the fault tolerance and integrity of multi-source data fusion. A dosage optimization module outputs a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and sends the command to the dosing actuator. Based on the previous dosing completion time of the dosing actuator, it performs isolated extrapolation of the pharmacodynamic increment during the interruption period, avoiding concentration calculation deviations caused by the superposition of unknown pharmacodynamic increments under communication interruption, ensuring the safety and reliability of pharmacodynamic assessment under fault conditions, and improving the adaptive adjustment capability of heatstroke drug dosage.
[0033] Please see Figure 2 As shown, it is a logical flowchart of the global timing calibration process based on the physiological event anchor point of heatstroke in an embodiment of the present invention.
[0034] Specifically, the data acquisition module is used to determine that the acquisition capability of multi-source clinical data meets the requirements when the sampling interval of multi-source clinical data is within the allowable range; The data acquisition module is used to transmit the multi-source clinical data to the fusion terminal.
[0035] Specifically, the data acquisition module is used to determine that the acquisition capability of the multi-source clinical data does not meet the requirements when the sampling interval of the multi-source clinical data exceeds the allowable range; The data acquisition module is used for global time-series calibration based on physiological event anchors of heatstroke.
[0036] In this embodiment, the allowable range for the sampling interval can be set by those skilled in the art, with the primary goal of achieving the desired result.
[0037] Specifically, the data acquisition module is used to extract multi-channel physiological features through a sliding window to form a candidate set of physiological event anchors for heatstroke, and to remove false anchors based on the physiological priors of heatstroke. The data acquisition module is used to match cross-channel source anchor points, fit the clock drift model of each channel, correct the timestamps of all sampling points, verify the anchor point deviation and iteratively optimize, and complete the timing alignment of multi-source non-uniform sampling data.
[0038] In this embodiment, the data acquisition module extracts clinical signal features channel by channel through a sliding time-domain analysis window, identifies pulse wave peak, systolic blood pressure peak, diastolic blood pressure trough, respiratory inflection point and body temperature change abrupt change point, and constructs a candidate set of physiological event anchor points specific to heatstroke. We introduce physiological prior constraints for severe heatstroke, eliminate false anchor points caused by interference or distortion, retain real and valid anchor points, retrieve homologous anchor points corresponding to the same real physiological moment in different acquisition channels, use this physiological moment as a global benchmark, compare the timestamp deviation of the valid anchor points in each channel, fit an independent clock drift model for each channel, and construct a global time-series distortion mapping function. This mapping function is used to uniformly recalibrate the timestamps of all original sampling points in each channel within the current window and map them to the same global time reference axis. After calibration, consistency verification is performed on all homologous anchor points. If the residual deviation exceeds the preset threshold, the window range is narrowed and iteratively optimized until the deviation meets the requirements. Finally, time-standardized and calibrated multi-source clinical data are output and sent to the data fusion module.
[0039] In this embodiment, the system performs global time-series calibration based on the sampling interval of multi-source clinical data and anchor points of heatstroke physiological events. Due to fluctuations in the power supply of the sensor front-end circuit, the timing accuracy of the sampling clock of the analog-to-digital conversion module drifts, causing the time interval between two adjacent samples to exceed the allowable range. This results in excessive deviation of the sampling interval of multi-source clinical data. By performing global time-series calibration based on anchor points of heatstroke physiological events, physiological characteristic events of heatstroke such as pulse peak and arterial blood pressure systolic peak can be used as natural time-series anchor benchmarks. Homologous physiological anchor points are selected to fit the clock drift model of each channel, achieving global calibration of the timestamps of all sampled data. This reduces the deviation of drug dosage optimization results caused by time-series errors and further improves the adaptive adjustment capability of heatstroke drug dosage.
[0040] Please see Figure 3 As shown, it is a logical flowchart of the dynamic anchoring correction process of the fusion timing reference in an embodiment of the present invention.
[0041] Specifically, the data fusion module is used to determine that the multi-source fusion feature vector is complete based on the fact that the arrival time of the previous valid data from the single data source is not earlier than the start time of the current fusion cycle. The data fusion module is used to fuse the multi-source clinical data to obtain a multi-source fusion feature vector.
[0042] Specifically, the data fusion module is used to determine that the multi-source fusion feature vector is incomplete if the arrival time of the previous valid data from the single data source is earlier than the start time of the current fusion cycle. The data fusion module is used to perform dynamic anchoring correction of the fusion time series benchmark.
[0043] Specifically, the data fusion module is used to dynamically select at least two highly reliable data sources as time-series reference channels and extract physiological events to generate flexible time-series beats; The data fusion module is used to map historical data from disconnected data sources to a flexible time-series axis and redefine the effective boundary, quantify the time-series lag offset to obtain the risk coefficient, and adopt a differentiated fusion strategy based on the risk coefficient. The data fusion module is used to continuously monitor the communication status of the reference channel and re-elect the reference channel when an anomaly occurs.
[0044] In this embodiment, the data fusion module first constructs a set of candidate time-series anchor channels for time-series calibration, selects monitoring channels that have a direct impact on the determination of drug administration strategy and have excellent communication reliability as candidate channels, specifically including the core body temperature monitoring channel and the invasive arterial blood pressure monitoring channel. The system counts the data packet transmission delay, packet loss rate and continuous online communication duration of each candidate channel in real time, and dynamically selects at least two candidate channels with stable and uninterrupted communication based on communication quality parameters, and determines them as global time-series anchoring benchmark channels. Using the current data fusion window as the analysis interval, physiological time-series features are extracted from the selected baseline channels to identify the inherent physiological time-series events of blood pressure systolic peak and pulse wave peak, and a flexible time-series beat sequence is generated based on the continuous physiological event sequence. For data sources with communication interruptions, the timestamp of the last set of valid data is mapped to a flexible timeline, the valid boundaries are redefined, and the validity of the data is dynamically determined in combination with the physiological state reflected by the baseline channel. By comparing the corresponding position of the historical valid data from the disconnected data source on the flexible time-series axis with the current fusion window position, the data time-series lag offset is accurately calculated. At the same time, combined with the real-time change rate of physiological indicators obtained from the baseline channel monitoring, a quantifiable time-series offset risk coefficient is generated. Based on this, a hierarchical differentiated fusion strategy is implemented: when the risk is low, the historical data is weighted by confidence and then used for fusion; when the risk is high, direct reuse is prohibited, and model inference or isolation of the abnormal source is used instead.
[0045] In this embodiment, the system dynamically anchors and corrects the fusion timeline benchmark based on the arrival time of the previous valid data from a single data source. If the communication channel of a data source is interrupted, the fusion unit may fail to receive new valid data from that data source at the start of the current fusion cycle. This results in at least one data source having its previous valid data arrival time remaining at the point in the previous fusion cycle, causing its previous valid data arrival time to be earlier than the start time of the current fusion cycle. Through dynamic anchoring and correction of the fusion timeline benchmark, a high-priority clinical data source with stable communication can be dynamically selected as the timeline benchmark. A flexible timeline axis is constructed based on physiological events in the benchmark channel, recalibrating the valid time boundary of expired historical data from the interrupted data source, quantifying the risk of timeline lag, suppressing drug dosage assessment bias caused by timeline misalignment, and further improving the adaptive adjustment capability of heatstroke drug dosage.
[0046] Please see Figure 4 As shown, it is a logical flowchart of the process of deducing and correcting the incremental drug efficacy during the intermittent period in an embodiment of the present invention.
[0047] Specifically, the dosage optimization module determines that the command execution capability of the drug delivery actuator meets the requirements if the completion time of the previous drug delivery is not earlier than the start time of the current processing cycle. The dosage optimization module is used to output a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and send the dosing adjustment command to the dosing actuator.
[0048] Specifically, the dosage optimization module is used to determine that the command execution capability of the drug delivery actuator does not meet the requirements if the time of completion of the previous drug delivery by the drug delivery actuator is earlier than the start time of the current processing cycle. The dosage optimization module is used to perform isolation simulation of drug efficacy increment during interruption.
[0049] Specifically, the dosage optimization module is used to switch to the drug efficacy increment isolation simulation mode based on the identified fault characteristics; The dosage optimization module is used to define an isolation window based on the start of the current treatment cycle in order to perform a one-way deduction of drug elimination to obtain a conservative efficacy state. The dosage optimization module is used to output a conservative dosing adjustment strategy based on the conservative pharmacodynamic state.
[0050] In this embodiment, the dosage optimization module monitors the operation status of the drug delivery link in real time. When it detects fault characteristics such as the drug delivery completion register not being refreshed, the communication link being interrupted, and the instruction execution status being unable to be verified, it automatically switches to the drug efficacy increment isolation simulation mode. The isolation simulation window is defined at the starting point of the current processing cycle. The latest reliable pharmacodynamic baseline data before the dosing instruction is issued is extracted, including the plasma drug concentration baseline, effect-site drug concentration and pharmacodynamic effect value. Only the parameters related to the natural elimination kinetics of the drug are retained. At the same time, the infusion dosage and pharmacodynamic increment calculation parameters corresponding to the dosing instruction to be confirmed are temporarily sealed. The natural decay change of the drug in the body is calculated according to the first-order elimination kinetics to obtain the conservative pharmacodynamic state. Using this conservative efficacy state as the basis for dosing calculations, a conservative dosing adjustment strategy prioritizing safety is output.
[0051] In this embodiment, the system uses the previous dosing completion time of the dosing actuator and performs an isolation deduction of the drug efficacy increment during the interruption. Due to the interruption of the communication link between the dosing actuator and the dosage optimization module, the dosing actuator failed to successfully complete the infusion operation corresponding to the received dosing adjustment command. As a result, the previous dosing completion time recorded in the dosing completion time register remains at the time when the dosing interruption occurred, instead of progressing to the normal completion time of the current processing cycle. This causes the previous dosing completion time of the dosing actuator to be earlier than the start time of the current processing cycle. By performing an isolation deduction of the drug efficacy increment during the interruption, the system can start the isolation deduction of the drug efficacy increment when communication is interrupted and the dosing execution status cannot be confirmed. This isolates the drug efficacy increment corresponding to the uncertain dosing command and performs conservative drug efficacy calculations based only on the drug natural elimination model. This prevents the risk of overestimation of concentration caused by the continuous accumulation of unknown drug efficacy increments, ensures uninterrupted system monitoring during the fault, avoids generating dangerous dosing plans based on incorrect drug efficacy status, and further improves the adaptive adjustment capability of heatstroke drug dosage.
[0052] The technical solution of the present invention has been described above with reference to the preferred embodiments shown in the accompanying drawings. However, it will be readily understood by those skilled in the art that the scope of protection of the present invention is obviously not limited to these specific embodiments. Without departing from the principles of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will all fall within the scope of protection of the present invention.
Claims
1. A heatstroke drug dosage optimization system integrating multi-source clinical data, characterized in that, include: The data acquisition module is used to collect multi-source clinical data from users in parallel through several detection devices, and to determine whether the sampling capacity of multi-source clinical data meets the requirements based on the sampling interval of the multi-source clinical data. The data fusion module is used to fuse the multi-source clinical data to obtain a multi-source fusion feature vector, and to perform dynamic anchoring and correction of the fusion timeline benchmark based on the arrival time of the previous valid data from a single data source. The dosage optimization module is used to output a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and send the dosing adjustment command to the dosing actuator to perform an isolation simulation of the pharmacodynamic increment during the interruption based on the dosing completion time of the previous dosing by the dosing actuator.
2. The heatstroke drug dosage optimization system integrating multi-source clinical data according to claim 1, characterized in that, The data acquisition module is used to determine whether the multi-source clinical data acquisition capability meets the requirements when the sampling interval of the multi-source clinical data is within the allowable range. The data acquisition module is used to transmit the multi-source clinical data to the fusion terminal.
3. The heatstroke drug dosage optimization system integrating multi-source clinical data according to claim 2, characterized in that, The data acquisition module is used to determine that the multi-source clinical data acquisition capability does not meet the requirements when the sampling interval of the multi-source clinical data exceeds the allowable range. The data acquisition module is used for global time-series calibration based on physiological event anchors of heatstroke.
4. The heatstroke drug dosage optimization system integrating multi-source clinical data according to claim 3, characterized in that, The data acquisition module is used to extract multi-channel physiological features through a sliding window to form a candidate set of physiological event anchors for heatstroke, and to remove false anchors based on the physiological priors of heatstroke. The data acquisition module is used to match cross-channel source anchor points, fit the clock drift model of each channel, correct the timestamps of all sampling points, verify the anchor point deviation and iteratively optimize, and complete the timing alignment of multi-source non-uniform sampling data.
5. The heatstroke drug dosage optimization system based on multi-source clinical data according to claim 4, characterized in that, The data fusion module is used to determine that the multi-source fusion feature vector is complete based on the fact that the arrival time of the previous valid data from the single data source is not earlier than the start time of the current fusion cycle. The data fusion module is used to fuse the multi-source clinical data to obtain a multi-source fusion feature vector.
6. The heatstroke drug dosage optimization system integrating multi-source clinical data according to claim 5, characterized in that, The data fusion module is used to determine that the multi-source fusion feature vector is incomplete if the arrival time of the previous valid data from the single data source is earlier than the start time of the current fusion cycle. The data fusion module is used to perform dynamic anchoring correction of the fusion time series benchmark.
7. The heatstroke drug dosage optimization system integrating multi-source clinical data according to claim 6, characterized in that, The data fusion module is used to dynamically select at least two highly reliable data sources as time-series reference channels and extract physiological events to generate flexible time-series beats. The data fusion module is used to map historical data from disconnected data sources to a flexible time-series axis and redefine the effective boundary, quantify the time-series lag offset to obtain the risk coefficient, and adopt a differentiated fusion strategy based on the risk coefficient. The data fusion module is used to continuously monitor the communication status of the reference channel and re-elect the reference channel when an anomaly occurs.
8. The heatstroke drug dosage optimization system based on multi-source clinical data according to claim 7, characterized in that, The dosage optimization module determines that the command execution capability of the drug delivery actuator meets the requirements if the completion time of the previous drug delivery is not earlier than the start time of the current processing cycle. The dosage optimization module is used to output a dosing adjustment command based on the multi-source fusion feature vector and the heatstroke pharmacokinetics model, and send the dosing adjustment command to the dosing actuator.
9. The heatstroke drug dosage optimization system based on multi-source clinical data according to claim 8, characterized in that, The dosage optimization module is used to determine that the command execution capability of the drug delivery actuator does not meet the requirements if the time of completion of the previous drug delivery is earlier than the start time of the current processing cycle. The dosage optimization module is used to perform isolation simulation of drug efficacy increment during interruption.
10. The heatstroke drug dosage optimization system based on multi-source clinical data according to claim 9, characterized in that, The dosage optimization module is used to switch to the drug efficacy increment isolation simulation mode based on the identified fault characteristics; The dosage optimization module is used to define an isolation window based on the start of the current treatment cycle in order to perform a one-way deduction of drug elimination to obtain a conservative efficacy state. The dosage optimization module is used to output a conservative dosing adjustment strategy based on the conservative pharmacodynamic state.
Citation Information
Patent Citations
Medicine dosage optimization method based on thermoplegia clinical data
CN120412885A
